Dendritic cells in transplantation and immune-based therapies Journal Article


Authors: Young, J. W.; Merad, M.; Hart, D. N. J.
Article Title: Dendritic cells in transplantation and immune-based therapies
Abstract: Dendritic cells (DCs) are specialized, bone marrow-derived leukocytes critical to the onset of both innate and adaptive immunity. The divisions of labor among distinct human DC subtypes achieve the most effective balance between steady-state tolerance and the induction of innate and adaptive immunity against pathogens, tumors, and other insults. Maintenance of tolerance in the steady state is an active process involving resting or semimature DCs. Breakdowns in this homeostasis can result in autoimmunity. Perturbation of the steady state should first lead to the onset of innate immunity mediated by rapid responders in the form of plasmacytoid and monocyte-derived DC stimulators and natural killer (NK) and NK T-cell responders. These innate effectors then provide additional inflammatory cytokines, including interferon-γ, which support the activation and maturation of resident and circulating populations of DCs. These are critical to the onset and expansion of adaptive immunity, including Th1, Th2, and cytotoxic T-lymphocyte responses. Rodent models are now revealing important data about distinct DC precursors, homeostasis of tissue-resident DCs, and DC turnover in response to inflammation and pathological conditions like graft-versus-host disease. The use of defined DC subtypes to stimulate both innate and adaptive immunity, either in combination or in a prime-boost vaccine sequence, may prove most useful clinically by harnessing both effector cell compartments. © 2007 American Society for Blood and Marrow Transplantation.
Keywords: transplantation, homologous; clinical trial; nonhuman; animals; mice; dendritic cell vaccine; bone marrow; steady state; dendritic cell; steroid; in vitro study; transplantation; cytokine; th2 cell; antigen presentation; dendritic cells; hematologic malignancy; immunotherapy; gamma interferon; drug mechanism; cytotoxic t lymphocyte; graft versus host reaction; allogeneic hematopoietic stem cell transplantation; cell therapy; natural killer cell; fc receptor; autoimmunity; innate immunity; rodent; th1 cell; monocyte; adaptive immunity; homeostasis; gvhd; cyclosporin a; tacrolimus; bone marrow transplantation; graft vs host disease; graft vs tumor effect; rapamycin; leukocyte; immunotherapy, adoptive; toll like receptor; alemtuzumab; vaccine; immunosuppressive agent; allogeneic; chimerism; gvl; gvt; lectin receptor
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 13
Issue: Suppl. 1
ISSN: 1083-8791
Publisher: Elsevier Inc.  
Date Published: 2007-01-01
Start Page: 23
End Page: 32
Language: English
DOI: 10.1016/j.bbmt.2006.10.023
PUBMED: 17222766
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 14" - "Export Date: 17 November 2011" - "CODEN: BBMTF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James W Young
    318 Young